Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) Operating Expenses (2016 - 2025)

BioCorRx (BICX) has disclosed Operating Expenses for 16 consecutive years, with $6.2 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 453.95% to $6.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.5 million through Dec 2025, up 123.7% year-over-year, with the annual reading at $5.6 million for FY2025, 9.72% up from the prior year.
  • Operating Expenses hit $6.2 million in Q4 2025 for BioCorRx, up from $2.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $6.2 million in Q4 2025 to a low of $841650.0 in Q4 2023.
  • Historically, Operating Expenses has averaged $1.5 million across 5 years, with a median of $1.2 million in 2022.
  • Biggest five-year swings in Operating Expenses: tumbled 55.25% in 2021 and later skyrocketed 453.95% in 2025.
  • Year by year, Operating Expenses stood at $1.3 million in 2021, then decreased by 5.77% to $1.3 million in 2022, then tumbled by 33.66% to $841650.0 in 2023, then soared by 33.64% to $1.1 million in 2024, then surged by 453.95% to $6.2 million in 2025.
  • Business Quant data shows Operating Expenses for BICX at $6.2 million in Q4 2025, $2.6 million in Q3 2025, and $1.6 million in Q2 2025.